New cancer clinical trial: ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

Published on: February 20, 2018 at 12:00PM
Condition:   Colorectal Cancer Metastatic
Intervention:   Drug: ABI-009; nab-rapamycin; albumin-bound rapamycin
Sponsor:   Aadi, LLC
Not yet recruiting
http://ift.tt/2Hu6sKx